US Patent 11365241 High concentration anti-C5 antibody formulations
Patent 11365241 was granted and assigned to Alexion Pharmaceuticals on June, 2022 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
July 27, 2018
Date of Patent
June 21, 2022
Patent Applicant
Patent Application Number
16633930
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 11365241 High concentration anti-C5 antibody formulations
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
